Regenerating Bone. Restoring Life.
Our mission is to deliver safe, effective, and long-term therapies for bone diseases restoring strength, mobility, and quality of life
Learn MoreThe Problem We're Solving
Age-related bone diseases such as osteoporosis and osteoarthritis affect hundreds of millions worldwide and place a massive economic burden on healthcare systems. Today’s therapies focus largely on slowing bone loss or managing pain, yet they often come with side effects and deliver poor long-term outcomes especially in older adults, who are most vulnerable. We are developing a first-in-class oral peptide therapy that simultaneously regenerates bone and restores the vascular microenvironment essential for long-term skeletal health. By leveraging natural physiological pathways, our approach offers a safe, regenerative alternative to current treatments, unlocking the potential for lasting improvements in mobility, healing, and quality of life.
Regeneration Therapy in Action
At the heart of Nimverta’s innovation is a first-in-class peptide designed to mimic the body’s own regenerative signals. By engaging natural pathways that activate both bone formation and vascular development, our therapy restores the critical crosstalk between bone cells and blood vessels that is lost in disease and aging. This biomimetic approach allows us to reactivate the body’s innate healing potential, offering a safer and more durable alternative to conventional treatments that only slow degeneration or address symptoms.
Nimverta, a Zurich-based biotech startup,has secured Venture Kick’s Stage I funding and initial Innosuisse coaching support, marking a new phase in its mission to develop first-in-class peptide therapies for bone regeneration.
Read moreWe are happy to hear from you. Whether you’re reaching out for collaboration, partnerships, or general inquiries, feel free to contact us. Our team will respond promptly and assist you with any questions or information you need.
